Yogesh A Sonawane1, Yingmin Zhu2, Jered C Garrison1, Edward L Ezell1, Muhammad Zahid1, Xiaodong Cheng2, Amarnath Natarajan1,1,1,1. 1. Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, Departments of Pharmaceutical Sciences, Environmental, Agricultural and Occupational Health, and Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska 68022, United States. 2. Department of Integrative Biology and Pharmacology and Texas Therapeutics Institute, University of Texas Health Science Center, Houston, Texas 77030, United States.
Abstract
EPAC proteins are therapeutic targets for the potential treatment of cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline analogs that explore various functional groups. The most potent EPAC inhibitor 12a exists as a mixture of inseparable E (major) and Z (minor) rotamers. The rotation about the N-formyl group indeed impacts the activity against EPAC.
EPAC proteins are therapeutic targets for the potential treatment of n class="Disease">cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline analogs that explore various functional groups. The most potent EPAC inhibitor 12a exists as a mixture of inseparable E (major) and Z (minor) rotamers. The rotation about the N-formyl group indeed impacts the activity against EPAC.
Tetrahydroquinoline based natural
products and analogs are known to have a wide range of biological
activities including antin class="Disease">cancer effects.[1] An N-formyl tetrahydroquinoline analog CE3F4 is
used as an EPAC1-selective inhibitor.[2−4] EPAC proteins play a
role in numerous cellular processes, which include insulin secretion,
neurotransmitter release, integrin-mediated cell adhesion, cell survival,
apoptosis, gene transcription, and chromosomal integrity.[5−12] EPAC1 is overexpressed in humanpancreatic ductal adenocarcinoma
(PDAC) samples, but the mechanism of this overexpression is unclear.[11] Migration and proliferation are key events in
cancer progression,[13] and EPAC activation
has been shown to regulate the proliferation and migration of prostate
cancer cells.[14] As these cellular functions
are crucial for tumor growth and metastasis, EPAC might represent
an attractive therapeutic target in the treatment of cancers. Considering
the important roles EPAC proteins play in physiological processes,
the development of pharmacological probes that are isoform selective
has attracted significant attention.[15−17] Here, we report the
structure–activity relationship of tetrahydroquinoline (CE3F4)
analogs, which includes the characterization of absolute configuration
by X-ray crystallography. Our studies also revealed that the most
potent EPAC1 inhibitor exists as a mixture of inseparable rotamers.
Importantly, our studies reveal that the minor isomer is probably
the major contributor of the EPAC1 activity.
In order to explore
the role of the bromo substitutions (R1 and R2) on the phenyl ring, the stereochemistry
(*) at the n class="Gene">C-2 position and the role of the N-formyl
group (R3) on CE3F4, we synthesized a focused library of
tetrahydroquinoline analogs (Figure ). The key steps in the synthesis are (i) reduction
of the commercially available 6-fluoro-2-methylquinoline 1 to yield the racemic tetrahydroquinoline core, (ii) bromination
of the aryl ring, (iii) resolution using a chiral auxiliary, and (iv)
formylation of the tetrahydroquinolinenitrogen.
Figure 1
Positions on the tetrahydroquinoline
explored in the structure–activity
relationship studies.
Positions on the tetrahydroquinoline
explored in the structure–activity
relationship studies.To explore the role of the bromine atoms on the phenyl ring
we
generated analogs 3, 6, n class="Chemical">CE3F4, and 8. Unlike CE3F4, which is a 5,7-dibromo compound analog, 3 does not contain bromine atoms, analog 6 is
a 5-bromo analog, and analog 8 is a tribromo compound.
A Pt/C-catalyzed reduction of 6-fluoro-2-methylquinoline 1 yielded a 6-fluoro-2-methyltetrahydroquinoline core.[18] Formylation of tetrahydroqinoline 2 was accomplished using acetic anhydride and formic acid to generate
analog 3 (Scheme ).
Scheme 1
Synthesis of Tetrahydroquinoline Analogs
Reagents and conditions: (a)
5% Pt/C, AcOH, H2, rt, 16 h; (b) AlCl3, Br2, 1,2-dichloroethane, 60 °C, 3 h; (c) acetic anhydride,
formic acid, 0–50 °C, 6 h; (d) acetyl chloride, pyridine,
DCM, 0 °C, 2 h; (e) 10% HCl, EtOH, reflux, 4 h.
Synthesis of Tetrahydroquinoline Analogs
Reagents and conditions: (a)
5% Pt/C, n class="Chemical">AcOH, H2, rt, 16 h; (b) AlCl3, Br2, 1,2-dichloroethane, 60 °C, 3 h; (c) acetic anhydride,
formic acid, 0–50 °C, 6 h; (d) acetyl chloride, pyridine,
DCM, 0 °C, 2 h; (e) 10% HCl, EtOH, reflux, 4 h.
Complexation with aluminum chloride (n class="Chemical">AlCl3)
deactivates
the pyridine ring and increases the electron density at the 5- and
8-positions. Consequently, electrophilic aromatic substitution of
6-halogenated quinolines or tetrahydroquinolines results in 5-substituted,
8-substituted, or 5,8-substituted analogs. AlCl3/Br2-mediated bromination of 1 resulted in 5-bromo-6-fluoro-2-methylquinoline 4 as the major product. A Pt/C-catalyzed reduction followed
by formylation using acetic anhydride and formic acid yielded the
monobromo-N-formyl tetrahydroquinoline 6. Bromination using AlCl3/Br2 of analog 3 yielded CE3F4. Careful chromatography resulted in the isolation
of 8, the tribromo compound, as a minor product.
Analogs 9 and 7 were synthesized to assess
the role of the formyl group inn class="Chemical">CE3F4. The acetyl variant 9 was generated in two steps. The formyl group was removed from CE3F4
under acidic conditions to generate analog 7, which was
acetylated to generate 9.
Courilleau et al. reported
an SAR of n class="Chemical">tetrahydroquinoline analogs
which included compounds 6, 7, and 9 in Table .[3] The present study expands on this SAR
and includes additional analogs and characterization of all compounds
evaluated. The tetrahydroquinoline analogs were analyzed for their
ability to inhibit EPAC1 activation. EPAC1 was stimulated in the presence
of 10 and 50 μM of the tetrahydroquinoline analogs. The activity
of the inhibitors was screened using a BODIPY-GDP-based guanine nucleotide
exchange factor (GEF) activity assay of Rap1 as described previously.[19] The 5-bromo-substituted analog 6 was ∼3-fold more potent than analog 3 that does
not have the Br atom at the 5 position. The 5,7-dibromo analog CE3F4
was ∼4-fold more potent than the monobromo analog 6. Interestingly, adding another bromine atom at the C-8 position
resulted in a ∼2.5-fold loss of activity. A comparison of CE3F4, 9, and 7 shows that replacing the formyl group
with an acetyl in 9 or removal of the formyl group in 7 resulted in loss of activity. We also evaluated the R and S isomers of 3, 6, and 7 to determine the effect of the stereocenter
on EPAC activity (Table S1). The data shows that the presence of the formyl
group makes the R analogs more potent than the S analogs. For example, 6R is ∼3-fold
more potent than 6S. On the other hand, in the absence
of the formyl group the S analog is more potent than
the R analog (7S analog is ∼7-fold
more potent than 7R). Together, these demonstrate
that 1-formyl, 6-fluoro, and 5,7-dibromo substitution on the tetrahydroquinoline
is optimal for the inhibition of EPAC1 activity (Table ).
Table 1
Evaluation
of Tetrahydoquinoline Analogs
% EPAC
inhibition
no.
R1
R2
R3
R4
lowa
highb
3
H
H
CHO
H
5.3
5.0
6
Br
H
CHO
H
15.8
42.0
CE3F4
Br
Br
CHO
H
58.1
88.3
7
Br
Br
H
H
40.8
74.1
8
Br
Br
CHO
Br
23.6
46.0
9
Br
Br
COCH3
H
8.7
26.2
10 μM.
50 μM.
10 μM.50 μM.Coupling of 6-fluoro-2-methyl-1,2,3,4-tetrahydroquinoline 2 with n class="Chemical">tosyl-S-prolinoyl chloride resulted
in diastereoisomers 10a and 10b (Scheme ).[20] The diastereomeric mixture was column separable and the
individual isomers were separated using an isocratic 9:1, dichloromethane
and ethyl acetate mobile system. The absolute configuration of the
diastereoisomers was determined by X-ray crystallography analyses
(Figure S1). Bromination of the individual
isomers resulted in 12a and 12b (R)- and (S)-CE3F4). We also generated the
corresponding thioformyl isomers 13a and 13b using Lawesson’s reagent. The absolute configurations of 12a, 12b, 13a, and 13b were established by X-ray crystallography (Figure ).
Scheme 2
Synthesis of Tetrahydroquinoline Enantiomers
Reagents and conditions: (a)
tosyl-S-prolinoyl chloride, DIPEA, DCM, 5-10 °C,
30 min. reflux; (b) NaOEt, EtOH, reflux, 6 h; (c) acetic anhydride,
formic acid, 0–50 °C, 6 h; (d) AlCl3, Br2, 1,2-dichloroethane, 60 °C, 3 h; (e) Lawesson’s
reagent, toluene, 100 °C, 6 h.
Figure 2
X-ray crystal structures
of 12a, 12b, 13a, and 13b.
Synthesis of Tetrahydroquinoline Enantiomers
Reagents and conditions: (a)
tosyl-S-prolinoyl chloride, n class="Chemical">DIPEA, DCM, 5-10 °C,
30 min. reflux; (b) NaOEt, EtOH, reflux, 6 h; (c) acetic anhydride,
formic acid, 0–50 °C, 6 h; (d) AlCl3, Br2, 1,2-dichloroethane, 60 °C, 3 h; (e) Lawesson’s
reagent, toluene, 100 °C, 6 h.
X-ray crystal structures
of 12a, 12b, n class="Chemical">13a, and 13b.
1H NMR of n class="Chemical">12a and 12b revealed
that they exist as a mixture of two rotamers in a 3:1 ratio. It is
well-known that N-formyl compounds exist in a solution
as interconverting rotamers. Rotation about the N-formyl (N-CO) bond has been of great interest to
organic chemists.[21−23] NMR studies have been used to estimate the energy
barrier for the rotamer interconversion[24] in compounds such as N-formyl-1-bromo-4- hydroxy-3-methoxymorphinan-6-one,
the key intermediate in opiate synthesis.[25] We conducted a temperature-dependent NMR study to confirm that 12a indeed exists as a pair of interconverting rotamers in
solution.
We observed peak broadening for a subset of peaks
at higher temperatures,
which is due to the dynamic exchange between the two rotamers (Figure and Figure S2).
Figure 3
Variable-temperature 1H NMR
spectra of 12a in DMSO-d6 from 20 to 79 °C demonstrating
the presence of rotamers.
Variable-temperature 1H NMR
spectra of n class="Chemical">12a in DMSO-d6 from 20 to 79 °C demonstrating
the presence of rotamers.
A complete coalescence was observed for all signals at 79
°C.
The reversibility of these changes was verified when the experimental
temperature was returned to 25 °C. We used the data obtained
from the variable temperature NMR studies to calculate the energy
barrier. The energy barrier (avg) for the major to minor is 16.6 kcal/mol,
while the energy barrier (avg) for the minor to major rotamer is 15.9
kcal/mol (Table S2). The major rotamer
(E) is ∼0.7 kcal/mol more stable than the
minor rotamer (Z).We conducted NOESY experiments
with mixing times of 50, 200, and
400 ms to assign the signals for the two rotamers. The peak volumes
measured by the NOE experiments correlated with the distance between
the formyln class="Chemical">hydrogen atom and the hydrogen atom at the C-2 position
(Figure and Figure S3). To determine the rate of interconversion
we dissolved the crystals in DMSO-d6 for
a quick 1H NMR. Remarkably, we observed the rotamers in
a ∼3:1 ratio, indicating the rapid equilibration in a solution.
Figure 4
Major
and minor rotamers determined based on NOESY spectra.
Major
and minor rotamers determined based on NOESY spectra.A comparison of the NMR and crystallography study
resulted in a
rather puzzling conundrum wherein only the minor rotamer crystallized.
Crystallography data suggests that the packing interactions are probably
better in the minor rotamer. Thioamide is a well-known isosteric replacement
of n class="Chemical">amides. The larger charge transfer from N to S in thioamides results in increased C-N rotational barrier by ∼5 kcal/mol when compared
to the corresponding amides.[26] Based on
this, we speculated that a thioformyl analog (13a in Scheme ) will adopt the E geometry, consistent with the major rotamer of 12a. NMR studies revealed that analog 13a is a single rotamer
(Figure S4). NOESY studies revealed that
the N-thioformyl group indeed adopts the E conformation, which is consistent with what was observed
by X-ray crystallography (Figure , 13a and 13b).
We
also explored the solvent effect on the rotamer ratio (C6D6, CDCl3, n class="Chemical">CD2Cl2, CD3COCD3, and CD3CN) and found
that the major isomer was slightly more favored in the nonpolar solvents
(Figure S5). Since 12a and 12b will be used for biological studies, we wondered if the
rotamer ratio will be influenced by the presence of water. To test
this, we conducted 1H NMR studies with increasing ratios
of D2O/DMSO-d6. The rotamer
ratio of 3:1 was stable even at 40% D2O (Figure S6), indicating that the rotamers exist in aqueous
solutions.
We next explored the effect of the stereochemistry
at the C-2 position
with analogs n class="Chemical">12a and 12b on EPAC1 activity
and selectivity. The R-isomer 12a was
∼10-fold more potent against EPAC1 than the S-isomer 12b. The R-isomer was ∼7-fold
selective for EPAC1 over EPAC2; interestingly, the selectivity was
reversed with the S-isomer (Table ). This demonstrates that the enantiomers
engage EPAC1 and EPAC2 differently, and the cocrystal structure of
EPAC1 and EPAC2 with the enantiomers will reveal the differences in
their binding modes.
Table 2
Evaluation of 12a, 12b, 13a, and 13b
IC50 (μM)
EPAC1
EPAC2
12a
3.3 ± 0.4
22.3 ± 2.1
12b
31.3 ± 9.2
17.1 ± 3.5
13a
17.6 ± 6.5
N/D
13b
>100
N/D
Analog 13a is ∼5-fold less active thann class="Chemical">12a. This is because 12a exists as a mixture
of rotamers while 13a does not. Compound 13a adopts the conformation that corresponds to the major rotamer conformation
of 12a. The loss of activity associated with 13a suggests that the minor rotamer conformation of 12a is the major contributor to the EPAC1 activity. This is partially
supported by the lower activity observed with analog 8 (Table ) that could
potentially restrict access to the minor conformation due to steric
hindrance. The present study does not address if demethylation (2-position)
of analog 12 will eliminate the rotamers; i.e., the formyl
group on such an analog will adopt the conformation that corresponds
to the major rotamer in 12. It is also possible that
the rotamer distribution is dictated by hypothetical hydrogen bonds
between the formyloxygen atom and the hydrogen atoms at the 2-postion
methyl group and/or the 8-position on the phenyl ring.
In conclusion,
we report a route (24% overall yield) for gram-scale
synthesis of the EPAC1 inhibitor n class="Chemical">12a with low μM
potency. The structure–activity relationship study demonstrates
that the two bromine atoms and the formyl group are critical for activity.
Moreover, the importance of the stereochemistry at the C-2 position
on activity and selectivity of 12a was demonstrated.
Herein, we provide extensive chemical and structural characterization
of 12a. NMR studies revealed that 12a exists
as a mixture of inseparable rotamers in a 3:1 ratio. The minor 12a rotamer crystallized, indicating better packing interaction,
and when the crystals were dissolved they rapidly equilibrated to
the 3:1 ratio. Studies with the thio analog 13a revealed
that it exists as a single compound that corresponds to the major
rotamer in 12a. Importantly, EPAC activity studies with 12a, 12b, 13a, and 13b indicate that the minor rotamer could be the major contributor to
the EPAC1 activity.
Authors: Tamara Tsalkova; Fang C Mei; Sheng Li; Oleg G Chepurny; Colin A Leech; Tong Liu; George G Holz; Virgil L Woods; Xiaodong Cheng Journal: Proc Natl Acad Sci U S A Date: 2012-10-22 Impact factor: 11.205
Authors: M Grandoch; A Rose; M ter Braak; V Jendrossek; H Rübben; J W Fischer; M Schmidt; A A Weber Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640
Authors: Maria Orfanoudaki; Anja Hartmann; Mostafa Alilou; Thomas Gelbrich; Patricia Planchenault; Séverine Derbré; Andreas Schinkovitz; Pascal Richomme; Andreas Hensel; Markus Ganzera Journal: Mar Drugs Date: 2019-12-31 Impact factor: 5.118
Authors: Samantha C Berkey; Juan J Herrera; Max A Odem; Simran Rahman; Sai S Cheruvu; Xiaodong Cheng; Edgar T Walters; Carmen W Dessauer; Alexis G Bavencoffe Journal: Neurobiol Pain Date: 2019-12-04